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Background: The incidence of oligometastases to the brain in good performance status patients is increasing due
to improvements in systemic therapy and MRI screening, but specific management pathways are often lacking.
Methods: We established a multi-disciplinary brain metastases clinic with specific referral guidelines and standard
follow-up for good prognosis patients with the view that improving the process of care may improve outcomes.
We evaluated patient demographic and outcome data for patients first seen between February 2007 and
November 2011.
Results: The clinic was feasible to run and referrals were appropriate. 87% of patients referred received a localised
therapy during their treatment course. 114 patients were seen and patient numbers increased during the 5 years
that the clinic has been running as relationships between clinicians were developed. Median follow-up for those
still alive was 23.1 months (6.1-79.1 months). Primary treatments were: surgery alone 52%, surgery plus whole brain
radiotherapy (WBRT) 9%, radiosurgery 14%, WBRT alone 23%, supportive care 2%. 43% received subsequent
treatment for brain metastases. 25%, 11% and 15% respectively developed local neurological progression only, new
brain metastases only or both. Median overall survival following brain metastases diagnosis was 16.0 months (range
1–79.1 months). Breast (32%) and NSCLC (26%) were the most common primary tumours with median survivals of
26 and 16.9 months respectively (HR 0.6, p=0.07). Overall one year survival was 55% and two year survival 31.5%. 85
patients died of whom 37 (44%) had a neurological death.
Conclusion: Careful patient selection and multi-disciplinary management identifies a subset of patients with
oligometastatic brain disease who benefit from aggressive local treatment. A dedicated joint neurosurgical/
neuro-oncology clinic for such patients is feasible and effective. It also offers the opportunity to better define
management strategies and further research in this field. Consideration should be given to defining specific
management pathways for these patients within general oncology practice.
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Brain metastases occur in approximately 20-30% of all
cancer patients and have an incidence at least four times
higher than primary brain tumours [1]. The common pri-
mary sites that metastasise to the brain are lung (45-50%),
breast (10-30%), melanoma (5-20%), renal cell (7%) and
gastrointestinal tumours (6%). Presentation in the context
of an unknown primary also makes up a small proportion
of cases (5%) [1-3]. Recent epidemiological data have
suggested a very significant increase in brain metastases in
patients with common tumour types, primarily related to
improved systemic treatment [4].
Historically, brain metastases were considered to be
associated with a uniformly poor prognosis and whole
brain radiotherapy was the mainstay of treatment. This
view has changed gradually in the last two decades with
increasing interest in the use of surgery and radiosurgery
(RS). Randomised trial evidence now supports the use of
surgery and RS in addition to WBRT to improve survival
in patients with a single metastasis [5-7]. An increased
focus on local treatment for oligometastatic disease is in-
creasingly relevant due to improved systemic therapies
in several common cancers, leading to better control of
extra-cranial disease and earlier diagnosis of brain me-
tastases due to more widespread use of MRI. In addition,
development in radiotherapy technology has made RS
more widely available thereby providing a local treat-
ment option for some patients in whom surgery would
not be deemed appropriate. An increasing proportion of
patients with brain metastases may therefore be candi-
dates for more aggressive local management aimed at
optimising local control in brain.
Patient selection for treatment of brain metastases has
been addressed by several different approaches to strati-
fication according to prognostic factors [8-10]. The
RTOG Prognostic Assessment (RPA) classification is the
most widely used and validated. Class 1 and 2 patients
are usually considered appropriate for aggressive treat-
ment [11]. Recent publications have suggested additional
subdivision based on more detailed information on the
status of non-brain metastatic sites and/or tumour biol-
ogy, which may refine this approach and improve selec-
tion further [10,12,13].
Recent randomised studies have added important data
on the role of surgery and RS with or without whole
brain radiotherapy in good prognosis patients with
oligometastases. Data from EORTC 22952–26001 sug-
gest equivalent survival following either modality (10.7
and 10.9 months) and local control rates of 69% and
41% at the treated lesion using RS or surgery respect-
ively [14]. Although local and distant recurrences in the
brain were reduced with the addition of WBRT, this did
not impact on survival. The authors suggest that with
MRI-based follow up, salvage treatment is effective inpreventing neurologic progression as a cause of death.
Design of this study reflects that fact that many clinicians
are moving away from routine use of adjuvant WBRT be-
cause of a concern about induction of neurocognitive def-
icit. Neurocognitive decline in a specific verbal memory
domain at 4 months after brain metastases treatment was
significantly associated with WBRT in a randomised study
[15]. However, very few studies have addressed this issue
and several data sets support the view that uncontrolled
metastatic disease is a more significant contributor to cog-
nitive problems and poor quality of life [16,17].
In the UK and other countries where there has been in-
creasing site specialisation among oncologists based on
primary disease site, there are specific issues in managing
patients with brain metastases since they present to their
site specialist team, often without links to a neuro-
oncology unit. Whilst management outside a neuro-
oncology setting may be appropriate for poor prognosis
patients, for others lack of access to a comprehensive
neuro-oncology opinion may impact on management and
outcomes. Lack of specialist management may also limit
information that is gathered at follow up and reduce ac-
cess to new treatment approaches within clinical studies.
Multidisciplinary team working is well established in
the management of cancer and joint surgical/ oncology
consultations may have a role, particularly where there
are several different treatment strategies that have to be
balanced against the individual’s circumstances. In view
of the changing demographics of metastatic brain dis-
ease we established a multi-disciplinary brain metastases
clinic in February 2007 specifically for patients with
good prognostic features with the hypothesis that im-
proving the process of care could improve clinical man-
agement and outcomes in such patients.
Methods
Clinic referral criteria
Specific referral guidelines were devised intended to in-
clude only patients in RPA classes 1 and 2 suitable for
aggressive local management of oligometastases. Patients
should meet all criteria:
 1-5 metastases
 >18 years
 Good performance status (KPS>60)
 Stable or low volume extracranial disease (recent
restaging required)
 All pathologies except lymphoma and germ cell tumours
 Location: supratentorial, posterior fossa, skull or
skullbase, dural-based or intra-axial
Clinic logistics
The clinic was held once a fortnight. The same core staff
with expertise in neurosurgery, RS and external beam
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(neuro-oncology), a neurosurgeon and cancer nurse spe-
cialist. Junior staff were not required. The general man-
agement principle of the clinic was to offer local therapy
(surgery or RS) without WBRT until proven progression
after surgery or RS, unless individual circumstances indi-
cated a need for upfront WBRT. Patients were seen in a
joint consultation simultaneously by all team members to
agree upon a treatment plan. The cancer nurse specialist
provided subsequent support to the patients and their
families and could involve social services, local palliative
care, occupational therapy and vocational rehabilitation as
appropriate. If systemic therapies were indicated these
would be under the care of the site-specific teams. The
same neurosurgeon carried out all elective brain metasta-
ses surgery, although all cases were discussed at the
neuro-oncology multi-disciplinary meeting (MDM) and
emergency cases treated by other neurosurgeons were
referred into the brain metastases service via the MDM.
Patients being considered for RS were also discussed at a
specific RS MDM prior to treatment.
The service was publicised to systemic oncologists
through departmental talks within the institution and in
nearby cancer centres served by our neurosurgical
services. The referral pathway is outlined in Figure 1. In
general patients known to have cancer were referred to
the clinical neuro-oncologist by their systemic oncolo-
gist. Referrals for those at first presentation usually cameFigure 1 Management of brain metastases pathway. The patient
continues to see their systemic oncologist for treatment/ monitoring
of extracerebral disease as required.through the neurosurgical department (referred in from
the local hospital, from our own emergency department
or hyper-acute stroke unit) and timely referral to the
appropriate local site specialist oncologist was then co-
ordinated through the metastasis clinic.
Patients were followed up at the brain metastases clinic
with contrast enhanced brainMRI scans at 3 monthly inter-
vals, for as long as further aggressive management of any
progressive brain disease was deemed appropriate. At the
time of progressive brain disease patients were re-evaluated
for further local therapy although there was a lower thresh-
old for adjunctive WBRT or partial brain irradiation (in-
cluding posterior fossa only, or tumour surgical bed).
Patients continued to see their systemic oncologist and re-
ceived systemic therapies as required. Responsibility for pa-
tients overall management was retained by their systemic
oncologist and they were able to enter any suitable studies
for treatment of their systemic cancer.
Demographic and outcome analysis
We analysed the demographics and outcomes of patients
first seen in the clinic between February 2007 and
November 2011 to establish whether appropriate pa-
tients were being seen and whether patient outcomes
supported the role of a dedicated clinic. The analysis
was carried out in May 2012 to allow at least 6 months
of follow-up per patient. Retrospective data were
collected from patient records and imaging held at our
institution, other treating hospitals, hospices and the GP.
Patient characteristics, treatment modalities, incidence
of local brain metastases progression, development of
new brain metastases and overall survival with cause of
death were analysed. A neurological cause of death was
defined as per Patchell et al. [5]. Performance status was
recorded in initial clinic documentation using the ECOG
scale. Where emergency surgery had been carried out
prior to the first clinic appointment performance status
was recorded as per the post-surgery clinic visit. To per-
mit RPA classification, ECOG score was converted to
Karnofsky Performance Status using the conversion table
proposed by Ma [18]. Where patients had been treated
elsewhere for brain metastases prior to referral to our
clinic, the actual date of brain metastases diagnosis and
the initial treatments given elsewhere were recorded in
our analysis.
Survival statistics and Kaplan Meier curves were
obtained using STATA version 12 and GraphPad Prism
version 4. Differences in survival between breast/ lung
primary histology and RPA class were assessed for statis-
tical significance using the logrank test. Survival according
to treatment modality are stated but differences between
treatment groups were not assessed for statistical signifi-
cance in view of the considerable impact of numerous
confounding factors in the non-randomised setting.
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Clinic activity
114 new patients were managed through the brain
metastases clinic (February 2007- November 2011).
There were typically 0–2 new patients and 1–3
follow-up patients per clinic in 2007 and 2–3 new pa-
tients and 4–6 follow-up patients per clinic in 2012.
Overall 25% of referrals involved patients in whom
brain metastases were their first diagnosis of cancer
and 52% involved the first presentation of brain me-
tastases in patients known to have cancer.18% of pa-
tients had initially been treated with WBRT by their
systemic oncologist and were referred to the brain
metastases clinic when brain progression had devel-
oped a considerable period of time after their original
WBRT. 46 patients were male and 68 were female
with a median age of 59 years (range 22–88 years).
72 patients (63.2%) had a single metastasis at initial
presentation, 22 (19.3%) had 2–3 metastases and 20
(17.5%) had ≥4 metastases. Breast and non small cell
lung cancer (NSCLC) were the most common pri-
mary tumours accounting for 31.6% and 26% respect-
ively. 94 patients (82.5%) had a controlled primary
tumour and although 66 patients (57.9%) had extra-
cerebral metastases, generally under control or with
effective systemic treatment options available. 106 pa-
tients (93%) were ECOG PS 0 or 1. These results
corresponded to 26 patients being in RPA class I, 80
patients in class II and 8 patients in class III. Demo-
graphic data are summarised in Table 1.
Following treatment over 90% of patients continued
scheduled follow up within the brain metastases clinic as
planned, a small number who lived further away were
monitored by their systemic oncologist only. WBRT was
provided by their systemic oncologist if this was more











87% of patients received a localised therapy during their
treatment course (n=99). Primary treatment was surgery
in 70 patients (surgery plus WBRT in 10 patients, sur-
gery plus RS in one patient), RS alone in 16 patients,
WBRT alone in 26 patients (including three with boost).
Of the patients who received primary WBRT alone, 20
(81%) had received it from their systemic oncologist at
least 18 months prior to referral to the brain metastases
clinic. Two patients received supportive care only as
they were of poor performance status and unlikely to
benefit from treatment. 40 patients (35.1%) received a
total of two lines of neurological treatment and 9 pa-
tients (7.9%) received three or more lines of treatment.
Second line treatment was WBRT in 24 patients, RS/
cyberknife (CBK) in 15 patients, surgery in 10 patients
Figure 3 Survival in patients with breast/lung primary.
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localised radiotherapy in 2 patients (one post surgery).
Subsequent lines of neurological treatment were WBRT
in 7 patients or RS/ CBK in 3 patients.
Outcomes
Data was available for all patients (unknown cause of
death for one patient). At the time of analysis, 29 patients
were still alive at a median follow-up of 23.1 months
(range 6.1 months to 79.1 months).
Local control and new brain metastases
Overall, 59 patients (52%) developed neurological progres-
sion: 29 patients (25.4%) developed local neurological pro-
gression only, 13 patients (11.4%) developed new brain
metastases only and 17 patients (14.9%) developed both
local progression and new brain metastases. Of the 30 pa-
tients who developed new brain metastases distant from
the original site, 12 (40%) had received WBRT as part of
their primary treatment and 18 (60%) had not. Overall 51
patients (44.7%) did not receive WBRT over the course of
their illness. Of the 35 patients who underwent upfront
WBRT alone or following surgery, 63% developed neuro-
logical disease progression: 10 patients local progression, 9
patients new brain metastases and 3 patients both.
Survival
Median overall survival from diagnosis of brain metasta-
ses was 16.0 months across all cancer types (range 1.0-
79.1 months) (Figure 2). One year survival was 55% and
two year survival 31.5%. When outcomes for the eight
patients in RPA class 3 are removed from the analysis,
overall median survival was 18 months for those in RPA
class 1 and 2 (three months in class 3). There was no sta-
tistically significant difference in median survival between
those in RPA class 1 and 2 (p=0.76). Median survival inFigure 2 Overall survival: all patients.breast cancer patients was 26.0 months and median
survival in lung cancer patients 16.9 months, (HR 0.6,
p=0.07) (Figure 3). There were 85 deaths in our series, of
which 37 (44% of deaths) were classed as neurological
deaths.
Table 2 summarises neurological outcomes and survival
for the major primary treatment modalities, however, it
must be emphasised that confounding factors prevent out-
come comparisons and that patients undergoing primary
WBRT had already usually survived for over 18 months
prior to referral to the clinic hence their apparent longer
survival.Discussion
Changes in the approach to managing systemic disease
in common tumour types associated with brain metasta-
ses and the evolving treatment options led us to set up a
specific multi-disciplinary clinic to manage good prog-
nosis brain metastases cases with the view that improv-
ing the process of care could improve outcomes in this
group.
The clinic has proven feasible to run with the same
oncologist, neurosurgeon and nurse specialist providing
continuity of care. The vast majority of patients seen
have met the referral criteria and aggressive local ther-
apy to their brain metastases has been appropriate. Only
a small number of patients in RPA class 3 attended the
clinic either because they had deteriorated in the time
since the referral was made or they had requested a sec-
ond opinion regarding their management. Patient num-
bers increased significantly over the last two years which
is likely to reflect the time taken to build relationships
between site specific teams and the increasing accept-
ance of locally aggressive management of brain metasta-
ses in selected patients within the oncology community.
Currently there are approximately 10 patients per clinic
and as our referral rate continues to increase we plan to
















Local New mets Both
Surgery alone 59 18 (30.5) 12 (20.3) 4 (6.8) 11 (18.6) 29 (49.2) 18 (30.5) 12 (1–79)
Surgery + WBRT 10 6 (60) 4 (40) 1 (10) 1 (10) 4 (40) 2 (20) 16 (8–46)
RS 16 1 (6.3) 2 (12.5) 3 (18.8) 1 (6.3) 6 (37.5) 5 (31.3) 13 (2–62)
WBRT * 23 3 (13.0) 7 (30.4) 5 (21.7) 3 (13.0) 10 (43.5) 9 (39.1) 23 (3–46)
Any 114 29 (25.4) 29 (25.4) 13 (11.4) 17 (14.9) 50 (43.9) 37 (32.5) 16 (1–79)
*most patients received WBRT from systemic oncologist at least 18 months prior to referral to brain metastases clinic.
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crease in referrals it seems likely that not all potentially
eligible patients are presently being considered for local-
ised therapy. A regional audit of brain metastases pa-
tients would be required to evaluate what fraction of
potentially appropriate referrals are seen.
Brain metastases were the first presentation of cancer
in 25% and standard site-specific cancer referral path-
ways do not generally include such patients, particularly
where diagnostic uncertainty exists regarding the pri-
mary. We have found that managing such patients
through the brain metastases clinic has streamlined the
organisation of staging investigations and onward refer-
ral to the appropriate local site-specific oncologist. Fur-
thermore, we have found that most patients with a new
cancer diagnosis find it helpful to receive some general
information regarding their cancer and possible further
treatment options which is more feasible within our
clinic compared to a standard neurosurgical clinic. Sup-
port for the patient and their family from the brain me-
tastases specialist nurse in the period prior to seeing the
systemic oncologist has proved useful. Concerns regard-
ing the potential of a “metastases-specific” clinic to com-
promise the decision-making autonomy of systemic
oncologists could be seen as a barrier to the develop-
ment of such services but we are clear to all patients
that the systemic oncologist maintains overall responsi-
bility for their care and we have not experienced any
conflicts. We have also found that patients are happy to
attend both their systemic oncology and brain metasta-
ses follow-up clinics. As patients are of good perform-
ance status, the extra clinic visit above standard care
does not appear to be a particular burden and over 90%
attended regular follow-up with us whilst they remained
fit enough for further treatment. Good communication
between specialists is obviously paramount when disease
progression occurs and to ensure that imaging is not du-
plicated. This was achieved by letter and phone call/
email if appropriate.
This is a deliberately highly selected group, but never-
theless our outcomes are encouraging and represent afairly typical cancer centre, treating patients referred
from routine oncology practice. The 18 month median
overall survival of our patients (RPA class 1 or 2) is con-
siderably better than the 7 and 4 months reported in
2000 by Gaspar et al. (RPA class 1 and 2) [11]. These pa-
tients had been treated in RTOG 91–04 and patient pro-
files were similar to ours but localised treatment was not
given. This serves to emphasise the importance of local-
ised therapy for brain metastases in appropriate patients
and the considerable improvements in the treatment of
systemic disease in the last decade. In some common
tumour sites effective systemic agents do not reach sites
of CNS disease and patients are at risk of neurologic
death despite controlled disease elsewhere [19] which
underlines the growing need to address CNS disease
separately. Without streamlined multidisciplinary man-
agement pathways for patients with brain metastases the
potential survival benefits of further improvements in
systemic therapies may not be realised; with further im-
provements in survival from systemic metastases more
patients are likely to live to develop brain metastases.
There are no trials offering a direct comparison be-
tween surgery and RS for oligometastases although avail-
able data suggest that local control rates are similar
[5,20,21]. A joint surgical/ oncology clinic can reduce
clinician bias in treatment decisions in other cancer
types [22,23] and we feel that the combined surgical and
oncology aspect of our clinic has been beneficial in tai-
loring treatment to the complex needs of patients with
brain metastases. It should be noted in our group that
patients treated with primary surgery included patients
presenting in emergency settings who may be expected
to do less well, whereas those treated with RS were
stable pre-treatment.
In the UK, the National Institute for Clinical Excel-
lence (NICE) guidance recommends that referral to
neuro-oncology is made for patients in whom brain me-
tastasis is the first presentation of disease or those with
a single metastasis and that RS should be available to pa-
tients with 1–2 metastases as an alternative to surgery.
Until recently RS has been available in only a limited
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tial proportion of patients have not had ready access to
RS. The recent expansion in the number of centres with
RS technology should reduce access issues but this un-
derlines the need to identify these patients appropriately
[24]. At the same time the availability of RS technologies
is encouraging treatment of patients with larger numbers
of brain metastases which may define additional sub-
groups of patients for whom this is effective treatment,
but this is reliant on comprehensive follow-up of patient
outcomes [25,26].
The debate continues regarding whether WBRT
should be routinely offered following localised therapy
for oligometastases to the brain [27]. Data from the
EORTC 22952–26001 study have shown that whilst “ad-
juvant” WBRT was associated with a lower rate of intra-
cranial progression and neurological death, overall
survival and functional independence were not improved
and that WBRT may negatively impact upon some as-
pects of quality of life [14,28]. Our policy was to with-
hold WBRT immediately after localised treatment unless
there was evidence of residual disease. 44% of deaths in
our study were from neurological causes with the major-
ity of other deaths due to progressive malignancy else-
where or thromboembolic events, which is consistent
with outcomes in the control arm of the EORTC study
[14]. 45% of our patients did not require WBRT in their
treatment course. Structured MRI follow-up is however
essential to identify disease progression in the brain
when treatment options were available. The American
College of Radiology recommends 3 monthly MRI in the
first instance extending to every 4–6 months [29]. Each
centre providing a brain metastases service should
develop a general policy with regard to WBRT and
follow-up.
Although our outcome results are promising, clearly
our patient group was highly selected and there are limi-
tations to our analysis. Significant bias prevents and
non-randomisation prevents efficacy comparisons be-
tween treatments which was not the purpose this report.
Due to small numbers, we were unable to calculate sur-
vival of less common primary tumours. Quality of life
and neuropsychology data was not available, specifically
level of functional independence influenced by neuro-
logical symptoms. We did not observe significant treat-
ment related toxicity from radiation-based treatments
but data on early toxicity following surgery were not
available.
Future advantages of treating patients in a specific
clinic setting include long-term collection of functional
outcome and treatment toxicity. We have now devel-
oped a formal database to prospectively collect data
and all patients will be offered neuropsychology assess-
ment. The clinic also offers a pathway to support theevaluation of MRI screening in patients at high risk of
brain metastases and we will shortly begin evaluating such
a policy in high risk patients with metastatic breast cancer
(HER-2 positive, hormone negative in the first instance). A
dedicated brain metastases clinic should also facilitate trial
participation in good prognosis patients and provide a reli-
able means of documenting long-term outcomes. Emer-
ging research topics in radiation therapy are whether it is
the number or volume of metastases that should be used
to define patients who likely to benefit from RS, the use of
RS to the tumour bed following surgery and the merits of
reducing radiotherapy to radiosensitive regions relevant to
changes in memory domains, such as the hippocampus
[30-32]. Historically patients with brain metastases have
been excluded from studies of novel systemic agents, but
the advent of small molecule targeted agents that pene-
trate CNS and the emergence of a good prognosis sub-
group of brain metastases patients should change this.
Within this group of patients there are very important
questions to be addressed including whether novel agents
can be selected based on primary tumour molecular gen-
etics and whether the agents that target neo-angiogenesis
will be effective in brain metastases.Conclusions
The epidemiology of brain metastases is changing. Ef-
fective systemic treatments are prolonging survival in
common cancers producing a population of “good prog-
nosis” patients with brain metastases who benefit from
multi-disciplinary management and rapid access to ef-
fective local treatment modalities. We found that a dedi-
cated joint clinic for such patients staffed by a specific
interested neurosurgeon, neuro-oncologist and specialist
nurse is feasible and effective. We did not experience
significant issues with communication/ decision making
between systemic oncology and neuro-oncology teams,
probably a result of the fact that multidisciplinary team-
work is now standard for many aspects of cancer care.
In our experience there is a sufficient need and promis-
ing survival data to support a dedicated clinic and con-
tinuing patient follow-up in this setting also offers the
opportunity to better define management strategies and
further research for this patient group. We would en-
courage other neurosurgical/ oncology centres to de-
velop similar models of care.
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